Actively Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Led by Hoffmann-La Roche · Updated on 2026-04-24
1600
Participants Needed
36
Research Sites
124 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
CONDITIONS
Official Title
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability and willingness to self-administer the study drug or receive injection from a trained individual if needed
- Diagnosis of type 2 diabetes mellitus with HbA1c between 6.5% and 10% and on stable oral therapy for at least 3 months prior to screening (if applicable)
- Body mass index (BMI) of 27.0 kg/m² or higher
- History of at least one unsuccessful attempt to lose weight with diet or exercise
You will not qualify if you...
- History of type 1 diabetes mellitus or ketoacidosis or hyperosmolar state/coma within 12 months before screening
- One or more episodes of severe hypoglycemia or hypoglycemia unawareness within 6 months before screening
- Two or more fasting blood glucose readings over 270 mg/dL during screening
- Weight change greater than 5 kg within 3 months before screening
- Obesity caused by other endocrine disorders or genetic/syndromic obesity
- Prior or planned surgical treatment for obesity (except liposuction or abdominoplasty done over 1 year ago)
- Known significant gastric emptying problems
- Poorly controlled hypertension at screening
- Cardiovascular events (heart attack, stroke, unstable angina, or heart failure hospitalization) within 3 months before screening
- Treatment with approved or investigational GLP-1 receptor-based therapies within 6 months before randomization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 36 locations
1
Lakeview Clinical Research
Guntersville, Alabama, United States, 35976
Actively Recruiting
2
Arizona Clinical Trials
Tucson, Arizona, United States, 85711
Actively Recruiting
3
Orange County Research Center
Lake Forest, California, United States, 92630
Actively Recruiting
4
Ark Clinical Research
Long Beach, California, United States, 90815
Actively Recruiting
5
Catalina Research Institute, LLC
Montclair, California, United States, 91763
Actively Recruiting
6
Prospective Research Innovations Inc.
Rancho Cucamonga, California, United States, 91730
Actively Recruiting
7
Emerson Clinical Research Institute
Washington D.C., District of Columbia, United States, 20009
Actively Recruiting
8
Progressive Medical Research
Port Orange, Florida, United States, 32127
Actively Recruiting
9
Elevate Clinical Research
Lake Charles, Louisiana, United States, 70605
Actively Recruiting
10
Centennial Medical Group
Columbia, Maryland, United States, 21045-5840
Actively Recruiting
11
Centricity Research Morehead City Multispeciality
Morehead City, North Carolina, United States, 28557
Actively Recruiting
12
Remington Davis Inc
Columbus, Ohio, United States, 43215
Actively Recruiting
13
Essential Medical Research
Tulsa, Oklahoma, United States, 74137
Actively Recruiting
14
Coastal Carolina Research Center
North Charleston, South Carolina, United States, 29405
Actively Recruiting
15
Circle Clinical Research
Sioux Falls, South Dakota, United States, 57104
Actively Recruiting
16
Velocity Clinical Research
Dallas, Texas, United States, 75230
Actively Recruiting
17
Juno Research, LLC
Houston, Texas, United States, 77040
Actively Recruiting
18
Manassas Clinical Research Center
Manassas, Virginia, United States, 20110
Actively Recruiting
19
Era Health Research
Redmond, Washington, United States, 98052
Actively Recruiting
20
CINME
Buenos Aires, Argentina, C1056ABI
Actively Recruiting
21
Paratus Clinical Western Sydney
Blacktown, New South Wales, Australia, 2148
Actively Recruiting
22
TGElliott Inc. dba BC Diabetes
Vancouver, British Columbia, Canada, V5Y 3W2
Actively Recruiting
23
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada, L6S 0C6
Actively Recruiting
24
LMC Clinical Research Inc
Toronto, Ontario, Canada, M4G 3E8
Actively Recruiting
25
Kasugai Municipal Hospital
Aichi, Japan, 486-8510
Actively Recruiting
26
Hasegawa Medicine Clinic
Hokkaido, Japan, 066-0032
Actively Recruiting
27
Higashijujo Sakai Diabetes Internal Medicine Clinic
Tokyo, Japan, 114-0001
Actively Recruiting
28
Changhua Christian Hospital
Changhua, Taiwan, 50006
Actively Recruiting
29
Chia-Yi Christian Hospital
Chiayi City, Taiwan, 600
Actively Recruiting
30
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan, 80756
Actively Recruiting
31
Chung Shan Medical University Hospital
Taichung, Taiwan, 40201
Actively Recruiting
32
China Medical University Hospital
Taichung, Taiwan, 40447
Actively Recruiting
33
National Cheng Kung University Hospital
Tainan, Taiwan, 70403
Actively Recruiting
34
National Taiwan University Hospital
Taipei, Taiwan, 10048
Actively Recruiting
35
Taipei Veterans General Hospital
Taipei, Taiwan, 112
Actively Recruiting
36
Division of Endocrinology and Metabolism;Internal Medicine
Chiang Mai, Thailand, 50200
Actively Recruiting
Research Team
R
Reference Study ID Number: WC45726 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here